News und Analysen
![Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application: https://www.marketbeat.com/logos/articles/med_20230530101326_chart-iova.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGNlYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5fd6ded371298788dd07c02b2ba5ece13592b28b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230530101326_chart-iova.jpg?locale=de)
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Administration (FDA). The company submitted, and
![A Reversal Is Brewing For Medtronic: Buying The Dip: https://www.marketbeat.com/logos/articles/med_20230525123637_chart-mdt-5252023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzhiYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--eff1552cffa82d7dd07608e3a72ecab7636f8a1a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230525123637_chart-mdt-5252023.png?locale=de)
A Reversal Is Brewing For Medtronic: Buying The Dip
A reversal has been brewing for Medtronic (NYSE: MDT) and healthcare device makers all year. Increasing procedure volume, supply chain normalization, and innovation drive results and underpinning
![Pfizer Has the Prescription for Higher Share Prices: https://www.marketbeat.com/logos/articles/med_20230524125944_pfizer-has-the-prescription-for-higher-share-price.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXdhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0c784121f528beec1f7021789f460466cc29d071/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230524125944_pfizer-has-the-prescription-for-higher-share-price.jpg?locale=de)
Pfizer Has the Prescription for Higher Share Prices
Pfizer Inc. (NYSE: PFE) released the results of a peer review study that sent shares up more than 5%. The study evaluated the company’s GLP-1 receptor agonist, danuglipron. The compound aimed to
![Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance: https://www.marketbeat.com/logos/articles/med_20230524090609_axcelis-stock-in-buy-range-after-chart-breakout-st.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1VaYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--00173f9481ee35c90dcd510bc7bc4a5bbe25e34c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230524090609_axcelis-stock-in-buy-range-after-chart-breakout-st.jpg?locale=de)
Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
Mid-cap chip-gear maker Axcelis Technologies Inc. (NASDAQ: ACLS) has been on a rocket ride, posting the following returns:
- 1 week: 9.68%
- 1 month: 13.66%
- 3 months: 14.26%
![Microbot Medical spikes 150% on its Endovascular Surgical Robot: https://www.marketbeat.com/logos/articles/med_20230523111957_chart-mbot.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEVYYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--07c59c148e09dd61653d60e4b9154801a95ae7cb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230523111957_chart-mbot.jpg?locale=de)
Microbot Medical spikes 150% on its Endovascular Surgical Robot
Microbot Medical Inc. (NASDAQ: MBOT) stock spiked more than 150% on a massive 194 million share volume on a successful pre-clinical animal study for its LIBERTY surgical robotic system. Shares hit
![2 Cheap Stocks And 1 Cheap Sector The Insiders Are Buying: https://www.marketbeat.com/logos/articles/med_20230523060816_2-cheap-stocks-and-1-cheap-sector-the-insiders-are.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEFXYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2853dfad3f2027d264624661693084e527acc4ff/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230523060816_2-cheap-stocks-and-1-cheap-sector-the-insiders-are.jpg?locale=de)
2 Cheap Stocks And 1 Cheap Sector The Insiders Are Buying
The insider buying activity is as interesting as usual, with some insiders selling and some buying. Among the more exciting details is that Warren Buffet started buying Occidental Petroleum (NYSE:
![Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine: https://www.irw-press.at/prcom/images/messages/2023/70633/Accesswire-Neurimmune_220523.001.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1lWYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4eed58c15c2cef3ad074a955184a356e9489f7b5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Accesswire-Neurimmune_220523.001.jpeg?locale=de)
Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine
Results also presented during late-breaking session at ESC Heart Failure congress 2023
ZURICH, SWITZERLAND / ACCESSWIRE / May 20, 2023 / Neurimmune announced today that primary results of
![Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?: https://www.marketbeat.com/logos/articles/med_20230518141428_is-pfizers-seagen-deal-in-jeopardy-amid-antitrust.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNk1UYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--828975049b596f383745f5396fd915be2235140a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518141428_is-pfizers-seagen-deal-in-jeopardy-amid-antitrust.jpg?locale=de)
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Pfizer Inc. (NYSE: PFE) continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.’s (NASDAQ: AMGN) planned acquisition of Horizon
![Zoetis Declares New Dividend, Hinting At Undervaluation: https://www.marketbeat.com/logos/articles/med_20230518102050_zoetis-declares-new-dividend-hinting-at-undervalua.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEVTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3c586cb6fc0711a2c928535d3df9a038565bda71/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518102050_zoetis-declares-new-dividend-hinting-at-undervalua.jpg?locale=de)
Zoetis Declares New Dividend, Hinting At Undervaluation
Zoetis (NYSE: ZTS) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company's first quarter 2023 announcements. Even
![Eagle Materials, Answering America's Building Supply Needs: https://www.marketbeat.com/logos/articles/med_20230518075018_eagle-materials-answering-americas-building-supply.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGNTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f5606e384c579396958e3c9f3e719cb3c303e913/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518075018_eagle-materials-answering-americas-building-supply.jpg?locale=de)
Eagle Materials, Answering America's Building Supply Needs
Shares of Eagle Materials (NYSE: EXP) are rallying in the pre-market hours of Thursday morning as the company releases its quarterly earnings results, which delivered an exceptional quarter
![Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market: https://www.marketbeat.com/logos/articles/med_20230518072301_pharma-giants-novartis-lilly-merck-and-novo-outper.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMHNTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1a176b59739d73a4cead553b293226e8f0f15add/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518072301_pharma-giants-novartis-lilly-merck-and-novo-outper.jpg?locale=de)
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Big pharmaceutical stocks, including Novartis AG (NYSE: NVS), Eli Lilly & Co. (NYSE: LLY), Merck & Co. (NYSE: MRK), and Novo Nordisk A/S (NYSE: NVO) have been outperforming the broader market
![Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings: https://www.marketbeat.com/logos/articles/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGtTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fe1fa8a76cffa1e1d1a7a5af6f98fc7532bc5f23/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg?locale=de)
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report.
Net income of $3.05 a
![Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential: https://www.marketbeat.com/logos/articles/med_20230517121722_analysts-say-these-2-mid-cap-biotechs-have-2x-pote.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG9TYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--efb5d185d67469d755d9527a295e82f9c42ac310/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230517121722_analysts-say-these-2-mid-cap-biotechs-have-2x-pote.jpg?locale=de)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel
![How to Invest in Telehealth and Telemedicine Stocks: https://www.marketbeat.com/logos/articles/med_20230517114005_telemedicine-stocks.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeUVSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e796a1efe22a38a79c5853f0e22bb11c6fbef543/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230517114005_telemedicine-stocks.png?locale=de)
How to Invest in Telehealth and Telemedicine Stocks
Coming into prominence during the COVID-19 pandemic, telemedicine stocks saw increases in price and profitability in the past five years. As relaxed government regulations allowed service
![Saturn Oil & Gas Inc. Reports Q1 2023 Results and Record Production: https://www.irw-press.at/prcom/images/messages/2023/70599/Saturn_170523_ENPRcom.004.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmNRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfe1718b0f96e0cef29f22e19f3c3d1ee5d51975/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_170523_ENPRcom.004.png?locale=de)
Saturn Oil & Gas Inc. Reports Q1 2023 Results and Record Production
CALGARY, ALBERTA – May 16, 2023 - Saturn Oil & Gas Inc. (TSXV: SOIL)(FSE: SMKA)(OTCQX: OILSF)(“Saturn” or the “Company”) is pleased to report its financial and operating results for the three
![Saturn Oil & Gas Inc. gibt Ergebnisse für 1. Quartal 2023 und Rekordproduktion bekannt: https://www.irw-press.at/prcom/images/messages/2023/70599/Saturn_170523_DEPRcom.004.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlFRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2ae4a6273fb7531fbea1a2791dc69f249162baac/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_170523_DEPRcom.004.png?locale=de)
Saturn Oil & Gas Inc. gibt Ergebnisse für 1. Quartal 2023 und Rekordproduktion bekannt
Calgary (Alberta), 16. Mai 2023 / IRW-Press / - Saturn Oil & Gas Inc. (TSX-V: SOIL) (FWB: SMKA) (OTCQX: OILSF) („Saturn“ oder das „Unternehmen“) freut sich, seine Finanz- und
![Beam Global Shines Brightly in the EV Infrastructure Space: https://www.marketbeat.com/logos/articles/med_20230516104836_beam-global-shines-brightly-in-the-ev-infrastructu.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEFQYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a1241f963ab54587246e9c02909d2bce5f18de1f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230516104836_beam-global-shines-brightly-in-the-ev-infrastructu.jpg?locale=de)
Beam Global Shines Brightly in the EV Infrastructure Space
Beam Global Inc. (NASDAQ: BEEM) is emerging as a standout in the electric vehicle (EV) infrastructure space. As the EV movement continues to spread as more EVs get on the road, EV charging
![The Turnaround for Weight Watchers is Taking Shape: https://www.marketbeat.com/logos/articles/med_20230514180546_charty-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGdPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff351f66c02189ec9ff23c0f8c44db4d7d59a6ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514180546_charty-ww.jpg?locale=de)
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares collapsed (26%) as Artal Group S.A
![Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy: https://www.marketbeat.com/logos/articles/med_20230516050346_sarepta-soars-31-as-fda-panel-backs-muscular-dystr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVFPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a31cb6b4ac8302cca8e5e70e3f6ee5c85d029040/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230516050346_sarepta-soars-31-as-fda-panel-backs-muscular-dystr.jpg?locale=de)
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
Sarepta Therapeutics Inc. (NASDAQ: SRPT) jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company’s experimental gene therapy to treat Duchenne
![Is Novavax Finally Turning Things Around?: https://www.marketbeat.com/logos/articles/med_20230514175918_chartt-nvax.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzBNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1adde23b9a3750d2f04deb8ca4ca0a45bf6b3fef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514175918_chartt-nvax.jpg?locale=de)
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious diseases, including COVID-19, influenza
![UnitedHealth Group is an AI Stock That Isn't Beating Expectations: https://www.marketbeat.com/logos/articles/med_20230515071148_unitedhealth-group-is-an-ai-stock-that-isnt-beatin.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzRNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--24e907afce9c48e7893a6e3910721cb7d1961c9b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230515071148_unitedhealth-group-is-an-ai-stock-that-isnt-beatin.jpg?locale=de)
UnitedHealth Group is an AI Stock That Isn't Beating Expectations
UnitedHealth Group Inc. (NYSE: UNH) is down 7.2% in 2023. The health maintenance organization (HMO) sector in general is lagging the market. So, investors may simply be taking a pause on a stock
![German International School of Silicon Valley wird für innovatives KI-Projekt mit hochdotiertem Preis der Deutschen Industrie- und Handelskammer (IHK) ausgezeichnet: https://www.irw-press.at/prcom/images/messages/2023/70502/GermanInternationalSchool_110523_DEPRcom.003.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFFKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--69267da7dcc2ba0d9abbf0e2be03b974f8f1a05d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/GermanInternationalSchool_110523_DEPRcom.003.jpeg?locale=de)
German International School of Silicon Valley wird für innovatives KI-Projekt mit hochdotiertem Preis der Deutschen Industrie- und Handelskammer (IHK) ausgezeichnet
MOUNTAIN VIEW und SAN FRANCISCO, KALIFORNIEN / ACCESSWIRE / 11. Mai 2023 / Die German International School of Silicon Valley (GISSV) wurde im Rahmen des von der Deutschen Industrie- und
![MicroVision Announces First Quarter 2023 Results: https://www.irw-press.at/prcom/images/messages/2023/70464/MICROVISION-PR-050923_PRcom.003.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0lHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d6e0d93a411e8808d069bb17e744224e1e951f58/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/MICROVISION-PR-050923_PRcom.003.png?locale=de)
MicroVision Announces First Quarter 2023 Results
REDMOND, WA / ACCESSWIRE / May 9, 2023 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2023
![MicroVision meldet Ergebnisse für das erste Quartal 2023: https://www.irw-press.at/prcom/images/messages/2023/70464/MICROVISION-PR-050923_DEPRcom.003.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0VHYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--246e9f85ae156e006aba8ca873121611ff8c8558/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/MICROVISION-PR-050923_DEPRcom.003.png?locale=de)
MicroVision meldet Ergebnisse für das erste Quartal 2023
Redmond, WA/ACCESSWIRE/9. Mai 2023/ MicroVision, Inc. (NASDAQ:MVIS), ein führender Anbieter von MEMS-basierten Festkörper-Automobil-LiDAR- und modernen Fahrerassistenzsystemen (ADAS), gab
![ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results: https://www.marketbeat.com/logos/articles/med_20230507142135_chartt-imgn.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEFEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c1a764fe2e456cda77e41a5778e3a020ec701a2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230507142135_chartt-imgn.jpg?locale=de)
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for